Validation of the ICON-S Staging for HPV-associated Oropharyngeal Carcinoma Using a Pre-defined Treatment Policy
Overview
Authors
Affiliations
Objectives: To determine whether the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) for HPV associated oropharyngeal carcinoma (HPV+OPC) is a better discriminator of overall survival (OS), compared with the 7th edition (7th Ed) AJCC/UICC TNM staging following curative radiotherapy (RT).
Material And Methods: The 5-year OS for all patients with non-metastatic (M0) p16-confirmed OPC treated between 2005 and 2015 was determined and grouped based on the 7th Ed AJCC/UICC TNM and ICON-S staging.
Results: A total of 279 patients met the inclusion criteria. The 5-year OS with the 7th Ed TNM classification were Stage I/II 88.9% (95% CI; 70.6-100%), Stage III 93.8% (95% CI; 85.9-100%), Stage IVa 86.4% (95% CI; 81.6-91.5%) and Stage IVb 62.3% (95% CI; 46.8-82.8%). On multivariate Cox regression analysis there was no statistically significant OS difference when comparing Stage I/II with, Stage III (p=0.98, HR=0.97, 95% CI; 0.11-8.64), IVa (p=0.67, HR=1.56, 95% CI; 0.2-11.94) and IVb (p=0.11, HR=5.54, 95% CI; 0.69-44.52), respectively. The 5-year OS with ICON-S staging were Stage I 93.6% (95% CI; 89.4-98.0%), Stage II 81.9% (95% CI; 73.7-91.1%) and Stage III 69.1% (95%; 57.9-82.6%). There was a consistent decrease of OS with increasing stage. On multivariate Cox regression analysis, when compared to Stage I, OS was significantly lower for stage II (p=0.007, HR=2.84, 95% CI; 1.33-6.05) and stage III (p<0.001, HR=3.78, 95% CI; 1.81-7.92), respectively.
Conclusion: The ICON-S staging provides better OS stratification for HPV+OPC following RT compared with the 7th Ed TNM staging.
Chun S, Kim E, Jang W, Kim M, Kang H, Kim B Cancer Res Treat. 2024; 56(4):1197-1206.
PMID: 38605662 PMC: 11491260. DOI: 10.4143/crt.2024.258.
Importance of the Number and Location of Lymph Node Metastasis in Oropharyngeal Cancer.
Iida M, Murai T, Kuno M, Osumi K, Nakanishi-Imai M, Okazaki D In Vivo. 2023; 37(5):2210-2218.
PMID: 37652496 PMC: 10500500. DOI: 10.21873/invivo.13321.
Zabala A, Martin-Arregui F, Sagazola J, Santaolalla F, Santaolalla F Front Public Health. 2023; 10:1004039.
PMID: 36699893 PMC: 9868380. DOI: 10.3389/fpubh.2022.1004039.
Choi K, Song J, Hong J, Lee Y, Kang J, Sun D PLoS One. 2022; 17(8):e0273059.
PMID: 35960785 PMC: 9374241. DOI: 10.1371/journal.pone.0273059.
Vijayvargiya P, Trivedi S, Rupji M, Song H, Liu Y, Jiang R Oncologist. 2022; 27(1):48-56.
PMID: 35305095 PMC: 8842371. DOI: 10.1093/oncolo/oyab001.